Previous 10 | Next 10 |
Amarin (AMRN) provides business update, including preliminary FY 2020 revenue results. FY20 total net revenue is expected to be ~$610M. The company expects European regulatory approval for Vascepa in early 2021, with CHMP opinion expected in late January or February 2021.EMA approval expected...
Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European Regulatory Review and Submission of China Regulatory Application for VASCEPA ® (icosapent ethyl) Expected in Late Janu...
Matinas has an OM3 drug that has demonstrated a superior profile to Amarin's Vascepa. It has a platform and, unlike Amarin, a diverse pipeline. I hope the company will learn from Amarin's mistakes and ensure proper protection for its IP moat. For further details see: Mat...
A lot of people have written off Amarin (NASDAQ: AMRN) for dead. The stock sells for a little over three times revenue and three times the cash on the books. The biotech only has one drug, Vascepa. It's an amazing medication that reduces strokes and heart attacks among patients ...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January ...
Amarin (AMRN) rises 7% after announcing VASCEPA (icosapent ethyl)-related scientific findings during the NLA Scientific Sessions 2020, held from December 10 – 12, 2020. Following administration of VASCEPA, a unique prescription eicosapentaenoic acid ((EPA))-based therapy at 4...
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in outpati...
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VAS...
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that scientific findings that add to the growing body of knowledge on VASCEPA® (icosapent ethyl) will be presented during the National Lipid Association (NLA) S...
Amarin Corporation plc (AMRN) Piper Sandler 32nd Annual Virtual Healthcare Conference Dec 02, 2020, 10:00 AM ET Company Participants John Thero - President & CEO Conference Call Participants Yasmeen Rahimi - Piper Sandler Presentation Yasmeen Rahimi Thank you for joining our live Fireside...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...